ALK and non-small cell lung carcinoma: ALK inhibition is a known mechanism for inducing apoptosis [199], and cancer cells (such as non-small-cell lung cancers (NSCLCs) and RMS) are often dependent on ALK and ROS1 function, providing a reasonable rationale for evaluating crizotinib and ceritinib in these cancers [200].